

For Immediate Release
For Further Information Contact:
Andrew Fisher at (202) 483-7000
Email: Afisher@unither.com

**UNITED THERAPEUTICS ANNOUNCES PROMOTION OF
ROBERT ROSCIGNO TO VICE PRESIDENT, COMMERCIAL DEVELOPMENT**

Research Triangle Park, NC and Silver Spring, MD, November 6, 2002: United Therapeutics Corporation (NASDAQ: UTHR) announced today that Robert Roscigno, Ph.D. has been promoted to Vice President of Commercial Development. In his new position, Dr. Roscigno is responsible for worldwide commercial development of Remodulin® (treprostinil sodium) Injection, United Therapeutics' therapy for the treatment of pulmonary arterial hypertension. Dr. Roscigno previously served as Director, Commercial Development.

"I am extremely pleased to make this promotion," said Martine Rothblatt, United Therapeutics' Chairman and CEO. "Robert was one of the principal scientific developers of Remodulin, and has also been the key individual responsible for its commercial acceptance in the United States and overseas. This promotion is emblematic of our Company's emphasis on career growth for our most talented professionals."

Remodulin received United States Food and Drug Administration approval on May 21, 2002, Canadian Therapeutic Products Directorate approval on October 4, 2002, and approval from the Israeli Ministry of Health on October 31, 2002. United Therapeutics has submitted marketing applications for Remodulin in France, Switzerland and Australia, with additional European filings to follow approval in France.

United Therapeutics is a biotechnology company focused on combating cardiovascular, infectious and oncological diseases with unique therapeutic products.

* * *